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NEWS AND PERSPECTIVES
Since last year, Mr Lee, a 56-year-old tuberculosis
(TB) patient, has been locked up indefinitely,
perhaps for the rest of his life. Prior to that, he had
escaped from hospital before the end of his mul-
tiple drug-resistant TB treatment, and had strongly
expressed unwillingness to return to hospital for
treatment. Taiwan’s Centers for Disease Control
(CDC) announced his name, and he became a
wanted person. However, he has not been charged
with any crime. Instead, he suffers from an exten-
sively drug-resistant strain of TB (XDR-TB), which
is resistant to at least isoniazid and rifampicin
plus the two most powerful classes of second-line
antituberculous agents—the injectable agents and
the fluoroquinolones.1 XDR-TB is more difficult
to manage than multidrug-resistant TB (MDR-TB),
which is defined as being simultaneously resistant
to at least isoniazid and rifampicin. XDR-TB is
considered to be virtually untreatable. The World
Health Organization has reported that XDR-TB
has now been found in 45 countries.
TB has been treatable and curable for over 50
years, and it was believed to be eradicable in the
1950s; however, there were 8 million new cases
and 2 million deaths from TB in 2005.2 In Taiwan,
the annual incidence of TB has remained persist-
ently high, ranging from 74.1/100,000 popula-
tion in 2004 to 70.0/100,000 population in 2006,
and the mortality rate was 4.2/100,000 in 2004
and 4.3/100,000 in 2005 according to the Taiwan
CDC.3 The Taiwan Surveillance of Drug Resistance
in TB (TSDRTB) program demonstrated that com-
bined drug resistance rates were 11.3% in 2004
and 10.1% in 2005 for isoniazid; 7.5% in 2004 and
6.2% in 2005 for rifampicin; 4.3% in 2004 and
2.1% in 2005 for ethambutol; 10.6% in 2004
and 9.8% in 2005 for streptomycin; 20.4% in
2004 and 18.1% in 2005 for any first-line drug;
and 5.3% in 2004 and 4.0% in 2005 for MDR-TB.4
These resistance rates are higher than those re-
ported by the third TB global drug resistance sur-
veillance.5 A primary cause of drug resistance is
the failure of patients to complete a full course of
TB medication because hospitals and clinics in
Taiwan fail to maintain a steady supply of stan-
dard TB regimens based on the national guide-
lines.6,7 A substantial proportion of patients were
prescribed antituberculous treatment based on
chest X-ray findings alone, and a considerable
proportion was advised to stop treatment before
completing a full course.8 Resistance to anti-TB
drugs arises from selection of naturally occurring
mutants with innate resistance to drugs. Poor 
adherence to the therapeutic regimen, improper
prescribing by clinicians and drug interactions or
malabsorption can result in partial suppression
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of bacterial growth and the emergence of resistant
organisms. Once this resistance develops, treat-
ment is compromised, further resistance can
evolve and resistant organisms can be transmitted
to other people, leading to primary drug resist-
ance that may fail to respond to standard ther-
apy. However, while MDR-TB and XDR-TB might
be difficult to treat, they might not be as hard to
prevent. Therefore, it is crucial to evaluate the TB
services that are being provided by clinicians in
general health care facilities and prevent dropout
by directly observed therapy, thus preventing the
emergence of MDR-TB.9 Attention must also be
paid to infection control in hospitals and clinics:
many of the MDR-TB cases in Taiwan were found
in general clinics or hospital wards. TB control
strategies targeted at populations with high risk
are critically important. Moreover, the capacity for
prompt and accurate laboratory-based diagnosis
of TB and drug resistance must be strengthened.
The Ethics of Involuntary Detention of
Persons with Infectious TB
Is it a crime to live in a society with a highly 
infectious disease? An individual with a highly
infectious but non-communicable disease exist-
ing in a public environment has committed no
crime and remains well within his rights. How-
ever, if the individual is aware that his infectious
disease is communicable and life-threatening,
then he should choose to or be forced to separate
from healthy individuals in his environment. The
problem of untreatable TB is suddenly on the
rise. XDR-TB has emerged worldwide as a threat
to public health and TB control, raising concerns
of a future epidemic of virtually untreatable TB.
Also cases like Mr Lee’s are extremely rare in
Taiwan, it is a situation that public health officials
may have to confront more and more because of
the widespread and growing problem of MDR-
TB and XDR-TB around the world, including
Taiwan.4,10–12 As the diagnosis of MDR-TB and
XDR-TB can take several weeks, patients suspected
of having TB should, ideally, be isolated in an
acute infectious diseases setting while awaiting
anti-TB drug-susceptibility testing, and then triaged
for further management based on the results.
The use of involuntary detention may legiti-
mately be countenanced as a means to ensure
isolation and prevent infected individuals from
possibly spreading the infection to others. In
Taiwan, which had a total of 14,554 reported
cases of TB in 2007,13 10.3% were MDR-TB in
2004 and 10.1% were XDR-TB in 2005.4 Should
involuntary detention be the last resort? How peo-
ple infected with MDR-TB should be dealt with is
a matter of debate, and the XDR-TB strain raises
an ethical dilemma. TB is the second leading
cause of preventable illness worldwide. Unfortu-
nately, TB has not received a proportionate
amount of ethics attention. How well have de-
tention programs balanced the need to protect
the public’s health with the civil liberties of TB
patients? Has forcible isolation been used as a
substitute for addressing the underlying causes 
of nonadherence? Which is more important: the
protection of society or the protection of individ-
ual rights and freedom? Uncertainty among health
professionals regarding the ethical, social and
human rights implications of fighting the outbreak
shows that there is an urgent need to address
doubts and inaction in order to prevent an epi-
demic of XDR-TB in Taiwan. Detentions in hos-
pitals or other health care facilities should apply
to XDR-TB patients who refuse treatment. The
high profile case of Mr Lee has highlighted ethi-
cal and legal issues associated with confinement
in the case of XDR-TB, but there are many addi-
tional ethical issues in need of attention from
bioethicists, public health authorities and policy
makers.
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